Linked Data API

Show Search Form

Search Results

386886
star this property registered interest false remove filter
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
unstar this property answering dept sort name Health more like this
star this property hansard heading Bone Marrow Disorders more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether they will place in the Library of the House any publications resulting from the phase 3 clinical trials approved for the potential treatment of systemic amyloidosis or multiple myeloma; and what is the National Institute of Health Research’s assessment of progress in these areas. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL995 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
unstar this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
unstar this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL996 more like this
HL997 more like this
star this property question first answered
less than 2015-07-14T15:34:29.197Zmore like thismore than 2015-07-14T15:34:29.197Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf remove filter
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386887
star this property registered interest false remove filter
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
unstar this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether there are currently any trials for systemic amyloidosis in humans being conducted by the National Institute of Health Research charities or the commercial sector. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL996 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
unstar this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
unstar this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL995 more like this
HL997 more like this
star this property question first answered
less than 2015-07-14T15:34:29.297Zmore like thismore than 2015-07-14T15:34:29.297Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf remove filter
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386888
star this property registered interest false remove filter
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
unstar this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL997 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
unstar this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
unstar this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL995 more like this
HL996 more like this
star this property question first answered
less than 2015-07-14T15:34:29.553Zmore like thismore than 2015-07-14T15:34:29.553Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf remove filter
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this